[EVALUATION OF GENOMIC PARAMETERS IN DUCTAL BREAST CANCER PATIENTS AND THE ABILITY OF IT'S CORRECTION].
Jokhadze. T T; Gaiozishvili. M M; Buadze. T T; Sigua. T T; Namchelvadze. E E; Lezhava. T T
Key Findings
- lymphocytes show high DNA single‑strand breaks, chromosomal abnormalities, and chromatin condensation",
- ,
Practical Outcomes
- For biohackers and self‑experimenters, the results are not directly usable: the work is done on cancer patient cells in a lab, not on healthy people, and no dosage or safety data for Livagen are provided. It does not offer a protocol you can apply for longevity or performance, and the relevance to non‑cancer populations is unclear.
Summary
The study looked at blood cells from women with ductal breast cancer and found they had lots of DNA damage and chromosome problems. When those cells were treated in the lab with the peptide Livagen and cobalt ions, the damage decreased, suggesting a protective effect in this test setting.
Abstract
The level of DNA single strand breaks, chromosomal abnormalities and sister chromatid exchanges and the possibility of its normalization with oligopeptide bioregulator Livagen and cobalt ions in the lymphocyte culture from patients with breast cancer have been studied. The results show that the genome of ductal breast cancer patients is characterized by the high density of DNA single strand breaks, high frequency of chromosomal abnormalities and increased levels of chromatin condensation. The usage of Livagen and cobalt in the form of modifying agents has a protective effect by all studied parameters. The obtained results allow us to conclude that research of lymphocytes of ductal breast cancer patients using the analysis conducted by us, can be useful in assessing the therapeutic effect in the treatment of breast cancer patients.
Study Information
pubmed
2017